EUVIMEDEUVIMED entdecken
Crossref

Involvement of the JAK ‐ STAT pathway in the molecular landscape of tyrosine kinase fusion‐negative hypereosinophilic syndromes: A nationwide CEREO study

Matthieu Groh iD, Laurène Fenwarth, Mathilde Labro, Augustin Boudry, Elise Fournier, Mathieu Wemeau, Alice Marceau-Renaut, Rafael Daltro de Oliveira, Julie Abraham, Marly Barry, Philippe Blanche, Quentin Bodard iD und 31 weitere

American Journal of Hematology · 2024-06 · 99 (6) · 1108-1118

DOI: 10.1002/ajh.27306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 02.04.2024. Verfasst von Matthieu Groh und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, French National Reference Center for Hypereosinophilic syndromes (CEREO), Hôpital Foch, Suresnes, France. Hauptthemen laut MEDLINE: Hypereosinophilic Syndrome, Mutation, STAT5 Transcription Factor. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated using a custom NGS panel of 149 genes the mutational landscape of 64 consecutive adult patients with tyrosine kinase fusion‐negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive of myeloid neoplasm. At least one mutation was reported in 50/64 (78%) patients (compared to 8/44 (18%) patients with idiopathic HE/HES/HE US used as controls; p < .001). Thirty‐five patients (54%) had at least one mutation involving the JAK‐STAT pathway, including STAT5B ( n = 18, among which the hotspot N642H, n = 13), JAK1 (indels in exon 13, n = 5; V658F/L, n = 2), and JAK2 (V617F, n = 6; indels in exon 13, n = 2). Other previously undescribed somatic mutations were also found in JAK2 , JAK1 , STAT5B , and STAT5A , including three patients who shared the same STAT5A V707fs mutation and features consistent with primary polycythemia. Nearly all JAK‐STAT mutations were preceded by (or associated with) myelodysplasia‐related gene mutations, especially in RNA‐splicing genes or chromatin modifiers. In multivariate analysis, neurologic involvement (hazard ratio [HR] 4.95 [1.87–13.13]; p = .001), anemia (HR 5.50 [2.24–13.49]; p < .001), and the presence of a high‐risk mutation (as per the molecular international prognosis scoring system: HR 6.87 [2.39–19.72]; p < .001) were independently associated with impaired overall survival. While corticosteroids were ineffective in all treated JAK‐STAT‐mutated patients, ruxolitinib showed positive hematological responses including in STAT5A ‐mutated patients. These findings emphasize the usefulness of NGS for the workup of tyrosine kinase fusion‐negative HE/HES patients and support the use of JAK inhibitors in this setting. Updated classifications could consider patients with JAK‐STAT mutations and eosinophilia as a new “gene mutated‐entity” that could be differentiated from CEL, NOS, and idiopathic HES.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypereosinophilic SyndromeMutationSTAT5 Transcription FactorHumansMaleFemaleMiddle AgedAdultAgedJanus Kinase 2Signal TransductionJanus Kinase 1Aged, 80 and overPyrimidinesYoung Adult

Substanzen

STAT5 Transcription FactorJanus Kinase 2Janus Kinase 1Pyrimidines

Autor:innen und Institutionen

  • Department of Internal Medicine, French National Reference Center for Hypereosinophilic syndromes (CEREO), Hôpital Foch, Suresnes, France.
  • University of Lille, INSERM 1286 INFINITE, CHU de Lille, Lille, France.
  • Laboratoire d'Hématologie, Centre de Biologie Pathologie Génétique, CHU Lille, Lille, France.
  • Département de Statistiques, Délégation de la recherche clinique et de l'innovation, Hôpital Foch, Suresnes, France.
  • Département d'Hématologie, CH de Roubaix, Roubaix, France.
  • Centre d'Investigations Cliniques, Hôpital Saint-Louis, Hôpital St Louis, AP-HP, Paris, France.

ORCID-Profile: Matthieu Groh, Quentin Bodard, Cécile Morice, Franck E Nicolini, Catherine Roche-Lestienne, Nicolas Duployez

Zitieren

APA

Groh, M., Fenwarth, L., Labro, M., Boudry, A., Fournier, E., Wemeau, M., Marceau-Renaut, A., Daltro de Oliveira, R., Abraham, J., Barry, M., Blanche, P., Bodard, Q., Braun, T., Chebrek, S., Decamp, M., Durel, C. A., Forcade, E., Gerfaud-Valentin, M., Golfier, C., …, & CEREO Collaborators (2024). Involvement of the JAK ‐ STAT pathway in the molecular landscape of tyrosine kinase fusion‐negative hypereosinophilic syndromes: A nationwide CEREO study. American Journal of Hematology, 99(6), 1108-1118. https://doi.org/10.1002/ajh.27306

Vancouver

Groh M, Fenwarth L, Labro M, Boudry A, Fournier E, Wemeau M, et al. Involvement of the JAK ‐ STAT pathway in the molecular landscape of tyrosine kinase fusion‐negative hypereosinophilic syndromes: A nationwide CEREO study. American Journal of Hematology. 2024;99(6):1108-1118. doi:10.1002/ajh.27306

BibTeX
@article{Groh2024,
  author = {Groh, Matthieu and Fenwarth, Laurène and Labro, Mathilde and Boudry, Augustin and Fournier, Elise and Wemeau, Mathieu and Marceau-Renaut, Alice and Daltro de Oliveira, Rafael and Abraham, Julie and Barry, Marly and Blanche, Philippe and Bodard, Quentin and Braun, Thorsten and Chebrek, Safia and Decamp, Matthieu and Durel, Cécile-Audrey and Forcade, Edouard and Gerfaud-Valentin, Mathieu and Golfier, Camille and Gourguechon, Clément and Grardel, Nathalie and Kosmider, Olivier and Martis, Nihal and Melboucy Belkhir, Sarah and Merabet, Fatiha and Michon, Adrien and Moreau, Stéphane and Morice, Cécile and Néel, Antoine and Nicolini, Franck E and Pascal, Laurent and Pasquier, Florence and Pieragostini, Andrea and Roche-Lestienne, Catherine and Rousselot, Philippe and Terriou, Louis and Thiebaut-Bertrand, Anne and Viallard, Jean-François and Preudhomme, Claude and Kahn, Jean-Emmanuel and Lefevre, Guillaume and Duployez, Nicolas and CEREO Collaborators, CEREO Collaborators},
  title = {Involvement of the JAK ‐ STAT pathway in the molecular landscape of tyrosine kinase fusion‐negative hypereosinophilic syndromes: A nationwide CEREO study},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {6},
  pages = {1108--1118},
  doi = {10.1002/ajh.27306}
}
Kostenlos starten →